- $877.15m
- $371.52m
- $67.48m
Brief: Kura Oncology Receives Breakthrough Therapy Designation For Ziftomenib
Brief: Kura Oncology Reports First Patient Dosed In Trial Of KO-2806 Plus Cabozantinib In Renal Cell Carcinoma
Kura Oncology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Kura Oncology Q4 Operating Expenses USD 46.762 Million
Brief: Kura Oncology Doses First Patient In KOMET-008-008 Trial Of Ziftomenib In Combination With Standards Of Care, Including FLT3 Inhibitor, In Acute Myeloid Leukemia
Kura Oncology Inc expected to post a loss of 55 cents a share - Earnings Preview
Kura Oncology Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Kura Oncology Files Prospectus Relates To Offer And Resale From Time To Time Of Up To 8.69 Mln Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, HCA Healthcare, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Kura Oncology , Vertex Pharma, Nucor
Kura jumps after positive data from blood cancer treatment trial
Brief: Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
U.S. STOCKS ON THE MOVE-Tesla, Microsoft, BlackBerry
U.S. STOCKS ON THE MOVE-Netfilx, DuPont, Baker Hughes
U.S. STOCKS ON THE MOVE-Gold miners, TE Connectivity, Amphenol
Kura Oncology soars on $150 mln premium PIPE financing
Brief: Kura Oncology Announces Oversubscribed $150 Million Private Placement
Brief: Kura Oncology's Menin Inhibitor Ziftomenib Selected For The Leukemia & Lymphoma Society'S Pediatric Acute Leukemia Master Clinical Trial
Kura Oncology Inc reports results for the quarter ended in September - Earnings Summary